Table 2

Simulated results for screening strategies to prevent CRC*

Variable

Screening Strategy


No Screening

DNA3

DNA5

DNA10

FOBT1

SIGM5

COLO10


Total cases of CRC, n

2,917

2,435

2,654

2,710

2,129

2,253

1,780

CRC deaths, n

1,729

1,345

1,467

1,574

1,059

1,328

1,077

Perforation deaths, n

0

3

2

1

5

3

12

Reduction in CRC incidence, %

0

17

9

7

27

23

39

Reduction in CRC mortality, %

0

22

15

9

39

23

39

Life expectancy, year

15.7337

15.7476

15.7434

15.7400

15.7584

15.7477

15.7590

Total costs, thousand $

22,022

35,637

31,077

26,856

19,824

24,909

21,843

Incremental life-year saved, year

0

1,390

970

626

2,464

1,383

2,530

Incremental cost, thousand $

0

13,615

9,054

4,834

-2,198

2,887

-180

Incremental cost ($)/life-years saved compared with no screening

0

9,794

9,335

7,717

Dominant‡

2,087

Dominant‡

Incremental cost ($)/life-years saved:

DNA3vs. other screening strategies

--

--

--

--

Dominant†

Dominant†

Dominant†

DNA5 vs. other screening strategies

--

--

--

--

Dominant†

Dominant†

Dominant†

DNA10 vs. other screening strategies

--

--

--

--

Dominant†

Dominant†

Dominant†


Abbreviations: CRC, colorectal cancer; DNA3, stool DNA testing every 3 years; DNA5, stool DNA testing every 5 years; DNA10, stool DNA testing every 10 years; FOBT1, fecal occult blood testing every two year; SIGM5, sigmoidoscopy every 5 years; COLO10, colonoscopy every 10 years.

* Values obtain from a cohort of 100,000 persons 50 years of age who were followed for 25 years.

† The other screening strategy is more effective and less costly than stool DNA testing strategy.

‡ The screening is more effective and less costly than No Screening.

Wu et al. BMC Cancer 2006 6:136   doi:10.1186/1471-2407-6-136

Open Data